Insider buying
~$5.5K497 sh @ $11.12
Traded Nov 12 · filed 1 day later
Corvus Pharmaceuticals's Chief Business Officer paid $5.5K out of pocket for Corvus Pharmaceuticals shares. Shares held went up 17% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 11, 2026 · Filed Nov 13, 2026
Corvus Pharmaceuticals's Chief Business Officer paid $34K out of pocket for Corvus Pharmaceuticals shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$34,381
Shares × reported transaction price
$25K–$100K
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 1.1% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($3.18M)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-24. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
6 days after results of Nov 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $11.47 on Nov 11, 2026, 76% above its 52-week low and 55% below its high, little changed over the previous 30 trading days
52-week range $6.50 (Jan 13, 2026) to $25.52 (Jan 22, 2026), 26% of the way up, from 251 adjusted closes. 30 trading days earlier: $11.52 on Sep 30, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any CRVS insider since May 2024. Jeffrey Arcara's first open-market purchase of CRVS in filings since 2016
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
Insider buying
Traded Nov 12 · filed 1 day later
Corvus Pharmaceuticals's Chief Business Officer paid $5.5K out of pocket for Corvus Pharmaceuticals shares. Shares held went up 17% with this purchase.
Insider buying
Traded Nov 13 · filed the same day
Corvus Pharmaceuticals's Chief Business Officer paid $5.2K out of pocket for Corvus Pharmaceuticals shares. Shares held went up 14% with this purchase.
Insider buying
Traded Nov 13 · filed the same day
Corvus Pharmaceuticals's Chief Business Officer paid $5.4K out of pocket for Corvus Pharmaceuticals shares. Shares held went up 13% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.